Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, a BMO survey suggests.

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular dystrophy over safety issues, even as patients and investors expressed ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.

Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA’s request to voluntarily halt all shipments of Elevidys following a third death ...

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" with the regulator.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After ...

Sarepta Therapeutics laid off more than one-third of its workforce, or approximately 500 employees, the company announced Wednesday — a drastic cost-cutting move following the deaths of two ...

Sarepta Therapeutics SRPT -3.11% is restructuring, laying off 36% of its workforce and making changes to its executive team. The restructuring is expected to save $400 million a year, the gene ...

Sarepta Therapeutics confronted one of the most serious crises in its history on Friday, rebuffing a call from the Food and Drug Administration to halt all shipments of its gene therapy for ...